Crinetics Pharmaceuticals CRNX 深 沪
已收盘 12-19 16:00:00 美东时间
47.97
+2.830
+6.27%
华盛通- 最 高50.98
- 今 开45.31
- 成交量 91.76万股
- 最 低 43.04
- 昨 收 45.14
- 总市值 25.67亿
- 52周最高 53.49
- 市盈率 静 --
- 换手率 1.71%
- 52周最低 24.10
- 委 比 -60.65%
- 总股本 5350.58万
- 历史最高 62.53
- 量 比 0.87
- 振 幅 17.59%
- 历史最低 1.10
- 每 手 1
- 风险率 6.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Crinetics飙升26.6%，其肢端肥大症治疗药物获FDA批准
制药企业Crinetics Pharmaceuticals(CRNX)早盘飙升26.6%，获得美国FDA对肢端肥大症治疗药物Palsonify的批准。批准基于成功的三期试验，产品计划于10月初上市。这标志着Crinetics在罕见病治疗领域的重要里程碑。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
09-26 22:57
Crinetics(CRNX)涨超22% 生长激素紊乱治疗方案获FDA批准 料十月初在美国上市
金吾财讯 | Crinetics(CRNX)涨超22%，截至发稿，报43.8美元。 消息面上，此前FDA批准了其用于治疗肢端肥大症的药物，这是一种导致体内生长激素过多产生的罕见疾病。 据悉，这种名为Palsonify的药物是一种每日一次的口服治疗药物，公司预计它将在十月初在美国上市。此次批准基于两项三期试验的数据，试验中药物耐受性良好，并带来了快速且一致的生化控制和症状减轻。
09-26 22:35
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
Crinetics Pharmaceuticals will host its R&D Day event on June 26, 2025, in New York, discussing updates on its early-stage pipeline assets, portfolio strategy, and advancements in treating endocrine diseases.
06-16 12:00
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals granted stock options and RSUs to 20 new non-executive employees under its 2021 Inducement Plan. Stock options total 74,000 shares with an exercise price of $33.08 and RSUs total 48,850, both vesting over four years. The awards align with Nasdaq Listing Rule 5635(c)(4) and are conditioned on continued employment.
06-10 20:29
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
Crinetics Pharmaceuticals (CRNX) will participate in the Jefferies Global Healthcare Conference June 3-5, 2025 in New York. Their presentation is June 5 at 12:50 p.m. ET. The company focuses on developing novel therapeutics for endocrine diseases and tumors.
05-23 12:00
Crinetics Submits New Drug Application For Paltusotine For The Proposed Treatment And Long-Term Maintenance Therapy Of Acromegaly
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral,
2024-09-27 04:10
Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and maintains $90 price target.
2024-09-16 23:36
